Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
AAV Mediated CTLA-4 Gene Transfer to Treat Sjogren's Syndrome
Case ID:
TAB-2339
Web Published:
12/6/2022
Sjögren’s syndrome is an autoimmune disease that affects over 2 million Americans, primarily over the age of 40. One of the major outcomes of Sjögren's syndrome is xerostomia (dry mouth) that is caused by immune system attack on moisture producing salivary glands. Researchers at the National Institute of Dental and Craniofacial Research have developed a therapy that alleviates xerostomia in a murine model of Sjögren's syndrome. This technology consists of a local delivery of adeno-associated virus (AAV) mediated cytotoxic T-lymphocyte antigen 4 Immunoglobulin-G (CTLA4IgG) fusion protein to salivary glands. The system effectively blocks CTLA4 ligand interactions with T cell surface receptors, resulting in immune suppression and reversal of autoimmune-related xerostomia. Targeted delivery of the AAV-CTLA4-IgG system makes this invention a novel therapeutic for the prevention of xerostomia-associated pain and discomfort caused by Sjögren's syndrome.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Direct Link:
https://canberra-ip.technologypublisher.com/tech?title=AAV_Mediated_CTLA-4_Ge ne_Transfer_to_Treat_Sjogren%27s_Syndrome
Keywords:
Adeno-associated
Adeno-associated Virus
IB3XXX
IBXXXX
IXXXXX
Sjogren's
Sjogren's syndrome
Syndrome
T-LYMPHOCYTE
virus
Xerostomia
Bookmark this page
Download as PDF
For Information, Contact:
Vladimir Knezevic
Senior Advisor for Commercial Evaluations
NIH Technology Transfer
vlado.knezevic@nih.gov